Skip to content

Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS)

Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy: Impact on Ovarian Reserve.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04178876
Acronym
CLESS
Enrollment
64
Registered
2019-11-26
Start date
2019-09-13
Completion date
2023-06-01
Last updated
2019-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrioma

Keywords

endometrioma, ethanol, sclerotherapy, aspiration, ovarian reserve, endometriosis, AMH

Brief summary

The aim of this study is to compare two different laparoscopic surgical techniques (endometrioma stripping vs ethanol sclerotherapy) in terms of ovarian reserve (AMH levels), recurrence rate and pain relief.

Detailed description

Patients with pelvic pain (VAS score≥4) and ultrasound diagnosis of endometrioma \> 4cm candidate to surgical removal of endometrioma will be randomized into 2 group. One Group will undergo laparoscopical stripping technique; the other one will undergo laparoscopic aspiration and sclerotherapy using 95% ethanol. The women will be introduced with both operative options and they will be informed about the randomization . After an elaborate explanation about the study they will sign an informed consent form. the following data will be collected prior the operation: age, gravity & parity, operative history, general medical history, the cyst size, AMH (Anti Mullerian Hormone), symptoms related to endometriosis (through VAS score), fertility history including any fertility treatment in the past and planned pregnancy after the operation. The laparoscopy will take place in Fondazione Policlinico Gemelli IRCSS, Roma. in the study group the cyst content will be aspirated and flushed with normal saline. 95% sterile ethanol will be instilled into the cyst through a Nelathon catheter. Ethanol will be left in the cyst for 15 min then aspirated as completely as possible following normal saline flushing. In the control group we will follow the standard treatment which is cystectomy. The women will be followed at 1 , 3 , 6 and 12 months after the surgery.

Interventions

Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol

Endometrioma laparoscopic cystectomy

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Women between 18-35 years old * Women with ultrasound diagnosis of ovarian endometrioma ≥4cm (with or without deep infiltrating endometriosis) * History of dysmenorrhea and/or chronic pelvic pain * candidates for elective laparoscopy due to endometriosis.

Exclusion criteria

* \- Previous surgery for ovarian endometriosis * Evidence of premature ovarian failure (follicle stimulating hormone ≥40 international units/L) * Endocrinal disorders that might affect ovarian function (e.g., polycystic ovary syndrome, thyroid dysfunction, hyperprolactinemia) * Ultrasound suspicious of ovarian malignant disease according IOTA criteria * endometrial cyst \< 4 cm. • ethanol sensitivity.

Design outcomes

Primary

MeasureTime frameDescription
impact on ovarian reserve, in terms of reduction of serum AMH levelsup to 12 months after the laparoscopyThe AMH levels will be evaluated 1 month before the surgery and 1, 6 and 12 months after surgery.

Secondary

MeasureTime frameDescription
endometrioma recurrence rate for the two surgical techniquesup to 12 months after the laparoscopyUltrasound examination that demonstrate the presence/lack of ovarian cyst with sonographic features of endometrioma in the ovary where the procedure took place.
pain relief after surgeryup to 12 months after the laparoscopyThe severity of pelvic pain , assessed using a visual analogue scale with no-pain classified as 0 and worst imaginable pain as 10.

Countries

Italy

Contacts

Primary ContactAlessandra De Cicco Nardone, MD
alessandradecicco@gmail.com+393428235829

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026